David Kirn, 4D Molecular Therapeutics CEO (via website)

4D Mol­e­c­u­lar Ther­a­peu­tics ac­quires eye dis­ease as­set from Fortress Biotech sub­sidiary

Cal­i­for­nia-based biotech 4D Mol­e­c­u­lar Ther­a­peu­tics (4DMT) will be ac­quir­ing the rights to an as­set from a com­pa­ny un­der the Fortress Biotech um­brel­la.

On Mon­day, 4DMT an­nounced it has se­cured rights to the short-form hu­man com­ple­ment fac­tor H (sCFH) as­set from Ae­vi­tas Ther­a­peu­tics, a sub­sidiary of Fortress Biotech. The as­set, in­vent­ed at the Uni­ver­si­ty of Penn­syl­va­nia, is a form of a nat­ur­al in­hibitor of the in­flam­ma­to­ry com­ple­ment path­way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.